Please check your internet connection and try again.
# Tabgenixim (Cefixime)
## Overview
Tabgenixim is a brand name for **Cefixime**, a third-generation oral cephalosporin antibiotic. It exhibits bactericidal activity by inhibiting bacterial cell wall synthesis. It is stable to hydrolysis by many beta-lactamases.
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Acute bronchitis and acute exacerbations of chronic bronchitis
* Uncomplicated gonorrhea (cervical/urethral/rectal)
## Adult Dosing
* **General infections:** 400 mg daily, administered either as a single dose or 200 mg every 12 hours.
* **Uncomplicated gonorrhea:** 800 mg orally as a single dose.
## Pediatric Dosing
* **General infections (≥6 months):** 8 mg/kg/day orally, administered as a single dose or divided into two doses (4 mg/kg every 12 hours).
* **Maximum daily dose:** 400 mg.
## Dose Adjustments
* **Renal Impairment:** If CrCl < 60 mL/min, dose reduction or extension of the dosing interval is recommended.
* CrCl 21–60 mL/min: Reduce dose by 25%.
* CrCl < 20 mL/min: Reduce dose by 50%.
* **Hepatic Impairment:** No specific adjustments defined; use with caution.
## Contraindications
* Known hypersensitivity to cefixime or other cephalosporin antibiotics.
* History of severe hypersensitivity (e.g., anaphylaxis) to penicillins or other beta-lactams (cross-reactivity risk).
## Adverse Effects
* **Common:** Diarrhea (frequently dose-related), nausea, abdominal pain, dyspepsia.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome), and hematologic abnormalities (thrombocytopenia, leukopenia).
## Key Drug Interactions
* **Warfarin/Vitamin K Antagonists:** May enhance the anticoagulant effect by altering gut flora; monitor INR closely.
* **Probenecid:** May increase serum concentrations of cefixime by inhibiting renal excretion.
* **Carbamazepine:** Cefixime may potentially increase carbamazepine levels; monitor for toxicity.
## Monitoring
* Monitor for signs of hypersensitivity reactions during the first dose.
* Monitor stool frequency/consistency if diarrhea persists (evaluate for *C. difficile*).
* Periodic renal function assessment in patients on long-term therapy or with pre-existing renal impairment.
## Clinical Pearls
* **Bioavailability:** The suspension form has higher bioavailability than the tablet form; use caution if interchanging products.
* **Spectrum:** While it covers many Gram-negative organisms, it has limited activity against *Staphylococcus aureus* or *Enterococcus* species.
* **Gonorrhea:** Due to emerging resistance, local antibiograms and current CDC guidelines should always be consulted for first-line gonorrhea treatment protocols.
***
*Educational Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always verify current prescribing information, institutional protocols, and patient-specific factors with a licensed healthcare provider or official drug monographs before prescribing or administering medication.*
